oxaliplatin
Overview
Third-generation platinum agent forming DNA adducts; component of FOLFOX/FOLFIRINOX.
Evidence in the corpus
- Component of colorectal-style first-line regimens applied to appendiceal adenocarcinoma; GNAS-mut predominant MAAP had 6% first-line response rate vs 50% for RAS-mut predominant MAAP on FOLFOX-style therapy (P=.03) PMID:36493333.
- Component of pembrolizumab + trastuzumab + capecitabine + oxaliplatin (PTC) regimen in HER2-positive metastatic esophagogastric cancer (phase II, n=37): median PFS 13 months, ORR 89% PMID:37406106.
- Component of FOLFIRINOX (fluorouracil + irinotecan + oxaliplatin + leucovorin) — the most commonly used neoadjuvant chemotherapy regimen in the MSK resected PDAC cohort (n=1,360). KRASG12R patients were enriched among FOLFIRINOX-followed-by-resection patients (32.7% vs 17.9%; p=0.094), suggesting possible higher chemosensitivity of KRASG12R PDAC to oxaliplatin-containing regimens. PMID:39214094
- FOLFIRINOX (38% of curated cohort) and gemcitabine/nab-paclitaxel (37%) were the dominant first-line regimens in the MSK PDAC 2024 prospective cohort (n=2,336 patients, n=304 metastatic with OS analysis); backbone choice was not significantly associated with OS in the metastatic subset. PMID:39753968
- Mentioned in HCC systemic therapy review as part of FOLFOX4 chemotherapy regimen in the context of HCC treatment options PMID:24798001
- Oxaliplatin-containing regimens (FOLFOX) were used as first-line chemotherapy in the 295-patient metastatic EGC cohort (MSK-IMPACT); HRD/LST scores did not predict response, and MSI-H tumors had inferior cytotoxic PFS (4.8 vs 6.9 months, HR=0.4, P=0.027) PMID:29122777
Resistance mechanisms
- GNAS-mut predominant molecular subtype is associated with resistance to platinum/5-FU-based regimens in mucinous appendiceal adenocarcinoma PMID:36493333.
Cancer types (linked)
Sources
- PMID:36493333
- PMID:37406106
- PMID:39214094 — Wood et al. 2024, MSK resected PDAC cohort; FOLFIRINOX context and KRASG12R chemosensitivity.
- PMID:39753968 — Zhu et al. 2024, MSK PDAC 2024 (pdac_msk_2024); FOLFIRINOX as dominant first-line backbone in 2,336-patient cohort.
This page was processed by crosslinker on 2026-05-04. - PMID:24798001
This page was processed by wiki-cli on 2026-05-11. - PMID:29122777
This page was processed by wiki-cli on 2026-05-15.